Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Removal of physical restraints in long term care settings: clinical safety and harm
2013	Medical Services Advisory Committee (MSAC)	Gene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Mental health rehabilitation for children and adolescents – a literature overview of indications, outcomes and evaluation instruments]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Heating standards for clinical interventions: clinical evidence
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Computed tomography angiography versus computed tomography for the diagnosis and management of hyperacute stroke: a review of comparative clinical evidence and guidelines
2013	Medical Services Advisory Committee (MSAC)	Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Zostavax for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA core model for rapid relative effectiveness assessment. Pilot-ID: WP-SA-1]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transcendental meditation for posttraumatic stress disorder, depression, and anxiety: a review of clinical effectiveness
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Intraoperative radiation therapy in the treatment of breast cancer]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bioabsorbable stents for adults with coronary artery disease: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2013	Medical Services Advisory Committee (MSAC)	Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent)
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Regorafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Identifying ineffective interventions and health technologies: models and their implementation]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	GreenLight laser for the treatment of benign prostatic hypertrophy: a review of clinical and cost-effectiveness, and safety
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Efficacy and safety of percutaneous and transapical aortic valve implantation in the treatment of severe aortic stenosis. Systematic review]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Diabetes screening for asymptomatic adults: a review of the diagnostic accuracy, cost effectiveness, and guidelines
2013	Medical Services Advisory Committee (MSAC)	Insertion, replacement, or removal of a cardiac resynchronisation therapy device capable of defibrillation (CRT-D) for mild, moderate or severe chronic heart failure (NYHA II, III or IV)
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (Eylea) extension of approval - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Management of congestive heart failure in primary and community care: guidelines
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety
2013	Medical Services Advisory Committee (MSAC)	Single balloon enteroscopy
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Teriflunomide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Occupational therapy in children; Part 1 – Literature review on indications, utilisation and recommendations]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Procedures and tools for patients at risk for creutzfeldt-jakob disease: guidelines and identification
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nutritional supplementation for patients with cancer: clinical effectiveness and guidelines
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Medical Services Advisory Committee (MSAC)	Optical coherence tomography, for the diagnosis and monitoring of treatment effectiveness with aflibercept in patients with central retinal vein occlusion (co-dependent)
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Evidence requirements for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada: an analysis of seven high-risk medical devices
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nd:YAG laser for the treatment of patients with hidradenitis suppurativa: a review of the clinical effectiveness, cost-effectiveness, and safety
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-surgical debridement for chronic lower extremity wounds: clinical effectiveness and guidelines
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Linagliptin (Trajenta®) 5 mg film-coated tablets
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Afatinib (Gilotrif®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Kidney transplantation following cardiocirculatory death: a review of the clinical evidence and guidelines
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Glycopyrronium bromide (Seebri® Breezhaler®) 44 micrograms inhalation powder as hard capsules
2013	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The effectiveness and safety of rituximab (anti-CD20) in neurologic autoimmune diseases
2013	NIHR Health Technology Assessment programme	Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: a systematic review and economic evaluation
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-steroidal anti-inflammatory drugs for pain: a review of safety
2013	HAYES, Inc.	Autologous Stem Cell Transplantation (ASCT) for Metastatic Primitive Neuroectodermal Tumor (PNET)
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Quality of evidence in a systematic review on early skin-to-skin contact for mothers and their healthy newborn infants
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Lymphatic-Venous anastomosis for lymphedema: clinical and cost-effectiveness
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Aztreonam lysine (Cayston®) 75 mg powder and solvent for nebuliser solution
2013	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis. Update of Report No. 45
2013	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tuberculosis testing for correctional staff: diagnostic accuracy and guidelines
2013	HAYES, Inc.	Automated percutaneous lumbar discectomy
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for initiating antiretroviral therapy in hospital inpatients with HIV
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prostate cancer screening: a review of the guidelines
2013	Belgian Health Care Knowledge Centre (KCE)	Correction of refractive errors of the eye in adults – Part 2: laser surgery and intraocular lenses
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Urine drug screening in chronic pain patients on opioid therapy
2013	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Surgical aortic valve replacement with the ATS Enable® sutureless aortic valve for aortic stenosis
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Battery replacement and maintenance of deep brain stimulators: guidelines and recommendations
2013	HAYES, Inc.	Bilevel positive airway pressure for the treatment of obstructive sleep apnea in adults
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Thromboelastography-guided heparin use for the prevention of venous thromboembolism
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pain management for pediatric patients in the emergency department: guidelines
2013	Belgian Health Care Knowledge Centre (KCE)	Dissemination and implementation of clinical practice guidelines in Belgium
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on bone fracture healing
2013	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Renal denervation for resistant hypertension
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Misoprostol administration for the treatment of post-partum uterine atony: clinical effectiveness, safety, and guidelines
2013	HAYES, Inc.	Biological mesh for abdominal hernia repair
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Antihistamine agents added to opioid analgesia
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bladder instillation of gentamicin for the treatment of recurrent urinary tract infections: clinical evidence and guidelines
2013	Belgian Health Care Knowledge Centre (KCE)	General framework for a multidisciplinary quality manual for cardiac care networks
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Nutrition during hospitalization for pediatric bronchiolitis
2013	Blue Cross Blue Shield Association (BCBS)	Special Report: multiple molecular testing of cancers to identify targeted therapies
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Routine blood tests for patients in the intensive care unit: clinical effectiveness, cost-effectiveness, and guidelines
2013	HAYES, Inc.	Dry needling for myofascial pain in adults
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Dexmedetomidine for sedation of cardiac surgical patients
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Swabbing techniques for the detection of bacterial colonization in wounds: comparative clinical evidence and guidelines
2013	Belgian Health Care Knowledge Centre (KCE)	Supportive treatment for cancer – Part 3: Treatment of pain: most common practices
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Nebulized hypertonic saline treatment for infants with bronchiolitis
2013	Blue Cross Blue Shield Association (BCBS)	Breast-Specific Gamma Imaging (BSGI), Molecular Breast Imaging (MBI), or scintimammography with breast-specific gamma camera
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long term Use of Clopidogrel for Patients with Stents or Acute Coronary Syndrome: A Review of Clinical and Cost-effectiveness and Guidelines
2013	HAYES, Inc.	Endovascular repair of isolated iliac artery aneurysms
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Appropriate use of lumbar fusion surgery
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Management of diabetes in the long-term care population: a review of guidelines
2013	Belgian Health Care Knowledge Centre (KCE)	The decisional process for the choice of active surveillance in localized prostate cancer
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Oxygen saturation discharge thresholds for infants admitted with bronchiolitis
2013	Blue Cross Blue Shield Association (BCBS)	Special Report: exome sequencing for clinical diagnosis of patients with suspected genetic disorders
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines
2013	HAYES, Inc.	Extracorporeal shock wave therapy for chronic plantar fasciitis
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Management of back pain following cardiac electrophysiology procedures
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vaginal preparation prior to cesarean delivery: clinical evidence
2013	Belgian Health Care Knowledge Centre (KCE)	Organisation of aftercare for patients with severe burn injuries
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Scales for assessing inpatients' risk of accidental falls
2013	Blue Cross Blue Shield Association (BCBS)	Handheld radiofrequency spectroscopy for intraoperative margin assessment during breast-conserving surgery
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Photo-activated disinfection therapy for non-dental surgery: review of the clinical effectiveness
2013	HAYES, Inc.	Fecal calprotectin assay for management of crohn's disease
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Use of midodrine with vasopressors in the intensive care unit
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Frequently-overused technologies
2013	Blue Cross Blue Shield Association (BCBS)	Ocriplasmin for symptomatic vitreomacular adhesion
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Hemolysis and blood infusion pumps for patients receiving blood or blood components: standards and evidence-based guidelines: standards and evidence-based guidelines
2013	HAYES, Inc.	Gastric electrical stimulation for gastroparesis
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Physician training and credentialing for robotic surgery in obstetrics and gynecology
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Technologies assisting in remote consultations for the diagnosis of stroke: a review of the clinical evidence
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Routine replacement of peripheral intravenous catheters